115 related articles for article (PubMed ID: 1385719)
1. Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group).
Gelber RD; Goldhirsch A; Hürny C; Bernhard J; Simes RJ
J Natl Cancer Inst Monogr; 1992; (11):127-35. PubMed ID: 1385719
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
3. A quality-of-life-oriented endpoint for comparing therapies.
Gelber RD; Gelman RS; Goldhirsch A
Biometrics; 1989 Sep; 45(3):781-95. PubMed ID: 2790121
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy versus ovarian ablation as adjuvant therapy for breast cancer: impact on health-related quality of life in a randomized trial.
Groenvold M; Fayers PM; Petersen MA; Mouridsen HT
Breast Cancer Res Treat; 2006 Aug; 98(3):275-84. PubMed ID: 16541325
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer in the elderly.
Crivellari D; Aapro M; Leonard R; von Minckwitz G; Brain E; Goldhirsch A; Veronesi A; Muss H
J Clin Oncol; 2007 May; 25(14):1882-90. PubMed ID: 17488987
[TBL] [Abstract][Full Text] [Related]
6. National Institutes of Health Consensus Development Conference statement: adjuvant therapy for breast cancer, November 1-3, 2000.
National Institutes of Health Consensus Development Panel
J Natl Cancer Inst Monogr; 2001; (30):5-15. PubMed ID: 11773285
[TBL] [Abstract][Full Text] [Related]
7. Long-term quality of life in premenopausal women with node-negative localized breast cancer treated with or without adjuvant chemotherapy.
Joly F; Espié M; Marty M; Héron JF; Henry-Amar M
Br J Cancer; 2000 Sep; 83(5):577-82. PubMed ID: 10944595
[TBL] [Abstract][Full Text] [Related]
8. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
9. The best available adjuvant treatments are within the framework of clinical trials. The International Breast Cancer Study Group.
Goldhirsch A; Gelber RD; Castiglione M; Price KN; Rudenstam CM; Lindtner J; Collins J; Senn HJ; Cavalli F; Galligioni E
Isr J Med Sci; 1995; 31(2-3):144-54. PubMed ID: 7744584
[TBL] [Abstract][Full Text] [Related]
10. Parametric approaches to quality-adjusted survival analysis. International Breast Cancer Study Group.
Cole BF; Gelber RD; Anderson KM
Biometrics; 1994 Sep; 50(3):621-31. PubMed ID: 7981389
[TBL] [Abstract][Full Text] [Related]
11. Weight gain and quality of life in women treated with adjuvant chemotherapy for early-stage breast cancer.
McInnes JA; Knobf MT
Oncol Nurs Forum; 2001 May; 28(4):675-84. PubMed ID: 11383182
[TBL] [Abstract][Full Text] [Related]
12. What can be expected from the next generation of adjuvant breast cancer treatment?
Piccart-Gebhart M
Semin Oncol; 1999 Feb; 26(1 Suppl 3):22-5. PubMed ID: 10203267
[TBL] [Abstract][Full Text] [Related]
13. Reporting and interpreting adjuvant therapy clinical trials. International Breast Cancer Study Group (formerly Ludwig Group).
Gelber RD; Goldhirsch A
J Natl Cancer Inst Monogr; 1992; (11):59-69. PubMed ID: 1385720
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17.
Muss HB; Tu D; Ingle JN; Martino S; Robert NJ; Pater JL; Whelan TJ; Palmer MJ; Piccart MJ; Shepherd LE; Pritchard KI; He Z; Goss PE
J Clin Oncol; 2008 Apr; 26(12):1956-64. PubMed ID: 18332474
[TBL] [Abstract][Full Text] [Related]
15. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
16. [Patients' experience of breast cancer treatment].
Grønvold M; Jensen AB
Ugeskr Laeger; 2007 Sep; 169(37):3114-7. PubMed ID: 17877963
[TBL] [Abstract][Full Text] [Related]
17. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in women with breast cancer during the first year after random assignment to adjuvant treatment with marrow-supported high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin or tailored therapy with Fluorouracil, epirubicin, and cyclophosphamide: Scandinavian Breast Group Study 9401.
Brandberg Y; Michelson H; Nilsson B; Bolund C; Erikstein B; Hietanen P; Kaasa S; Nilsson J; Wiklund T; Wilking N; Bergh J;
J Clin Oncol; 2003 Oct; 21(19):3659-64. PubMed ID: 14512398
[TBL] [Abstract][Full Text] [Related]
19. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.
Pinder SE; Murray S; Ellis IO; Trihia H; Elston CW; Gelber RD; Goldhirsch A; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Gusterson BA
Cancer; 1998 Oct; 83(8):1529-39. PubMed ID: 9781946
[TBL] [Abstract][Full Text] [Related]
20. Factors correlated with fatigue in breast cancer patients before, during and after adjuvant chemotherapy: the FATSEIN study.
Rotonda C; Guillemin F; Bonnetain F; Conroy T
Contemp Clin Trials; 2011 Mar; 32(2):244-9. PubMed ID: 21078419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
